dihexa australia | 1401708-83-5 | BGC70883 DiHEXA - Cosmetic Dermatologist Dr.

Get In Touch

3 4 Systemic Regenerative Research Additional experimental investigations have explored BPC-157 across pancreatic, hepatic, cardiovascular, endothelial, skeletal muscle, ligament, tendon and bone injury models

Preclinical and clinical data show no significant toxicity at therapeutic doses

The bottom line: peptides like BPC-157 and TB-500 represent an active and legitimate area of regenerative research, but they are investigational compounds, not approved therapies

Unlike semaglutide which activates only GLP-1 receptors, or tirzepatide which targets GLP-1 and GIP, retatrutide simultaneously activates three hormone receptors

Treatment: Inj abdomen 1x daily